- Trial phase
- Approved (BLA 761291); marketed
- Time to market
- Already on the market, FDA-approved since Oct 2022 (BLA 761291, Type 1 new molecular entity, Priority review); latest label expansion approved Mar 2026.
- Why 3/10
- TECVAYLI is already approved and commercializing (original BLA approval Oct 2022; most recent efficacy supplement, the sBLA with DARZALEX FASPRO, was approved Mar 5, 2026) with no dated binary catalyst for this drug in the next ~12 months, and it is a minor value driver inside a ~$600B mega-cap, so the score sits at 3 per the approved-drug-with-no-pending-decision band.
TECVAYLI is not a JNJ stock-mover on its own: the defining binary (the March 2026 combo approval with DARZALEX FASPRO) has already passed, and JNJ does not break out TECVAYLI sales in its Q2 2026 earnings release, the myeloma franchise narrative is led by DARZALEX (+18.9% YoY) and CARVYKTI (+49.4%). For a non-medical investor, watch JNJ's quarterly oncology commentary and any future earlier-line readouts for this molecule, not TECVAYLI-specific events; the stock itself trades near consensus targets (~$272.5 mean) with very low short interest (~1.05% of est. shares outstanding).
Price Chart
Executive Summary
TECVAYLI (teclistamab-cqyv) is Johnson & Johnson's marketed bispecific antibody for relapsed/refractory multiple myeloma, developed by its Janssen Biotech unit (BLA 761291). It was approved in Oct 2022 and has been through several label expansions; the most recent, a Priority-review efficacy supplement approved Mar 5, 2026, added TECVAYLI in combination with DARZALEX FASPRO. It is a real, selling drug, but inside J&J it is one of several myeloma assets (DARZALEX and CARVYKTI were the growth drivers J&J highlighted in Q2 2026) and carries no upcoming hard catalyst, so it is immaterial to JNJ's share price on its own.
How It Works
TECVAYLI is an engineered antibody with two "arms": one latches onto a protein (BCMA) that sits on the surface of multiple myeloma cancer cells, and the other grabs CD3 on immune cells called T cells. This physically bridges the cancer cell to the T cell, forcing the immune system to kill the myeloma cells. It is given as a subcutaneous (under-the-skin) injection.
Trial Status
Originally approved Oct 25, 2022 as a first-in-class subcutaneous BCMA×CD3 bispecific for relapsed/refractory multiple myeloma, followed by multiple efficacy/labeling supplements (Feb 2024, Nov 2024, and the Priority-review sBLA #18 approved Mar 5, 2026 adding the combination with DARZALEX FASPRO). A Janssen-sponsored Phase 2 study in Japanese patients with relapsed/refractory multiple myeloma (NCT04696809, n=40) completed Apr 13, 2026.
The Two-Sided Case
Upcoming Catalysts
- None scheduled for TECVAYLI specifically in the next ~12 months in local FDA/trial data, the last regulatory event (sBLA #18 combo approval, Mar 5, 2026) has passed.
- Watch JNJ quarterly earnings (next 10-Q/earnings release cadence) for commentary on the myeloma franchise (DARZALEX, CARVYKTI, TECVAYLI, TALVEY) and any earlier-line label-expansion readouts.
- Phase 2 Japanese RRMM study (NCT04696809) completed Apr 2026 with results not yet posted, a low-impact data point, not a stock catalyst.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
JOHNSON & JOHNSON 8-K JNJ ·Originating report